Sensitivitätsanalyse und robustes Prozessdesign pharmazeutischer Herstellungsprozesse

The existence of parameter uncertainties(PU) limits model-based process design techniques. It also hinders the modernization of pharmaceutical manufacturing processes, which is necessitated for intensified market competition and Quality by Design (QbD) principles. Thus, in this thesis, proper approaches are proposed for efficient and effective sensitivity analysis and robust design of pharmaceutical processes. Moreover, the point estimate method (PEM) and polynomial chaos expansion (PCE) are further implemented for uncertainty propagation and quantification (UQ) in the proposed approaches. Global sensitivity analysis (GSA) provides quantitative measures on the influence of PU on process outputs over the entire parameter domain. Two GSA techniques are presented in detail and computed with the PCE. The results from case studies show that GSA is able to quantify the heterogeneity of the information in PU and model structure and parameter dependencies affects significantly the final GSA result as well as output variation. Frameworks for robust process design are introduced to alleviate the adverse effect of PU on process performance. The first robust design framework is developed based on the PEM. The proposed approach has high computational efficiency and is able to take parameter dependencies into account. Then, a novel approach, in which the Gaussian mixture distribution (GMD) concept is combined with PEM, is proposed to handle non-Gaussian distribution. The resulting GMD-PEM concept provides a better trade-off between process efficiency and probability of constraint violations than other approaches. The second robust design framework is based on the iterative back-off strategy and PCE. It provides designs with the desired robustness, while the associated computational expense is independent from the optimization problem. The decoupling of optimization and UQ provides the possibility of implementing robust process design to more complex pharmaceutical manufacturing processes with large number of PU. In this thesis, the case studies include unit operations for (bio)chemical synthesis, separation (crystallization) and formulation (freeze-drying), which cover the complete production chain of pharmaceutical manufacturing. Results from the case studies reveal the significant impact of PU on process design. Also they show the efficiency and effectiveness of the proposed frameworks regarding process performance and robustness in the context of QbD.Die pharmazeutische Industrie muss sowohl den gestiegenen Wettbewerbsdruck standhalten als auch die von Regulierungsbehörden geforderte QbD-Initiative (Quality by Design) umsetzen. Modellgestützte Verfahren können einen signifikanten Beitrag leisten, aber Parameterunsicherheiten (PU) erschweren jedoch eine zuverlässige modellgestützte Prozessauslegung. Das Ziel dieser Arbeit ist daher die Erforschung von effizienten Approaches zur Sensitivitätsanalyse und robusten Prozessdesign der pharmazeutische Industrie. Methoden, Point Estimate Method (PEM) und Polynomial Chaos Expansion (PCE), wurde implementiert, um effizient Unsicherheitenquantifizierung (UQ) zu erlauben. Der globalen Sensitivitätsanalyse (GSA) ist eine systematische Quantifizierung von Parameterschwankungen auf die Simulationsergebnisse. Zwei GSA Techniken werden im Detail vorgestellt und an Beispielen demonstriert. Die Ergebnisse zeigen sowohl den Mehrwert der GSA im Kontext des robusten Prozessdesigns als auch die Relevanz zur korrekten Berücksichtigung von Parameterkorrelationen bei der GSA. Um den schädlichen Einfluss von PU auf die modellgestützte Prozessauslegung zusätzlich zu minimieren, wurden weitere Konzepte aus der robusten Optimierung untersucht. Zunächst wurde das erste Konzept basierend auf der PEM entwickelt. Das erste Konzept zeigt einen deutlich reduzierte Rechenaufwand und kann auch die Parameterkorrelationen entsprechend in der robusten Prozessauslegung berücksichtigen. In einem zweiten Schritt wurde ein neuer Ansatz, der die Gauß-Mischverteilung mit der PEM kombiniert, hierzu für nicht normalverteilte PU erfolgreich implementiert. Weiterhin wurde eine iterative Back-off-Strategie erforscht, die auch die PU entsprechend berücksichtigt aber leichte Rechenaufwand zeigt. Durch die Entkoppelung von UQ und Optimierung können wesentlich komplexere pharmazeutische Herstellungsprozesse mit einer hohen Anzahl an PU implementiert werden. Die in dieser Arbeit untersuchten verfahrenstechnische Grundoperationen decken somit einen Großteil der gesamten Produktionskette der pharmazeutischen Herstellung ab. Die Ergebnisse der untersuchten Beispiele zeigen deutlich den Einfluss von PU auf das modellgestützte Prozessdesign auf. Mithilfe der vorgeschlagenen Approaches können die PU effektiv und effizient bei einer optimalen Balance von Rechenaufwand und der geforderten Zuverlässigkeit ganz im QbD-Sinne berücksichtigt werden

Space and biotechnology: An industry profile

The results of a study conducted by the Center for Space and Advanced Technology (CSAT) for NASA-JSC are presented. The objectives were to determine the interests and attitudes of the U.S. biotechnology industry toward space biotechnology and to prepare a concise review of the current activities of the biotechnology industry. In order to accomplish these objectives, two primary actions were taken. First, a questionnaire was designed, reviewed, and distributed to U.S. biotechnology companies. Second, reviews of the various biotechnology fields were prepared in several aspects of the industry. For each review, leading figures in the field were asked to prepare a brief review pointing out key trends and current industry technical problems. The result is a readable narrative of the biotechnology industry which will provide space scientists and engineers valuable clues as to where the space environment can be explored to advance the U.S. biotechnology industry

Quality by Design Procedure for Continuous Pharmaceutical Manufacturing: An Integrated Flowsheet Model Approach

Pharmaceutical manufacturing is crucial to global healthcare and requires a higher, more consistent level of quality than any other industry. Yet, the traditional pharmaceutical batch manufacturing has remained largely unchanged in the last fifty years due to high R&D costs, shorter patent durations, and regulatory uncertainty. This has led regulatory bodies to promote modernization of manufacturing process to continuous pharmaceutical manufacturing (CPM) by introducing new methodologies including quality by design, design space, and process analytical technology (PAT). This represents a shift away from the traditional pharmaceutical manufacturing way of thinking towards a risk based approach that promotes increased product and process knowledge through a data-rich environment. While both literature and regulatory bodies acknowledge the need for modernization, manufacturers have been slow to modernize due to uncertainty and lack of confidence in the applications of these methodologies. This paper aims to describe the current applications of QbD principles in literature and the current regulatory environment to identify gaps in literature through leveraging regulatory guidelines and CPM literature. To aid in closing the gap between QbD theory and QbD application, a QbD algorithm for CPM using an integrated flowsheet models is also developed and analyzed. This will help to increase manufacturing confidence in CPM by providing answers to questions about the CPM business case, applications of QbD tools, process validation and sensitivity, and process and equipment characteristics. An integrated flowsheet model will aid in the decision-making process and process optimization, breaking away from ex silico methods extensively covered in literature